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COMMENTARY
Who Will Care for Tomorrow’s Children With Benign
Hematological Conditions?
Over the past decades pediatric hematologists have greatly
contributed to the field of Medicine in a variety of ways. The
unraveling of the molecular basis of thalassemia for example has
enabled us to diagnose this disease pre-natally. Pediatric hematol-
ogists also identified the molecular basis for bone marrow failure
syndromes and chronic granulomatous disease, and established
effective treatments for iron overload in the hemoglobinopathies.
Moreover, pediatric hematologists were instrumental in developing
age appropriate strategies to diagnose and treat the coagulation
disorders and hypercoagulable states in childhood. However,
research opportunities continue to exist in this field. For example,
whowill identify the basis for fetal hemoglobin switching and define
other potential cures and disease modifiers for sickle cell disease?
There is a demand in transfusion medicine and opportunities for
pediatric hematologists to unravel molecular underpinnings and
treatments of a number of bone marrow failure syndromes,
including Shwachman Diamond syndrome, Diamond Blackfan
syndrome, and Dyskeratosis Congenita. These bone marrow failure
syndromes are all disorders in which ribosomal function is affected.
In part, there is much interest as to how ribosomal dysfunction
predisposes some patients to cancer. Then, based on the ongoing
need for (and therefore success of) the 1-800-NO-CLOTS service,
we suggest that the need for experts capable of managing patients
with complex bleeding and hypercoagulable disorders remains
unchanged. Finally, our field also needs to develop tomorrow’s
hemophilia center leaders. Today there about 150 federally funded
hemophilia centers mandated to manage and support affected
patients and their families. These programs provide great career
opportunities for pediatric hematologists. The work of pediatric
hematologists does certainly not seem over to us.
Given the ongoing demand for academic pediatric hematolo-
gists, we believe that there is a responsibility for today’s educational
leaders (Pediatric Chairs and Pediatric Hematology/Oncology
Division Chiefs and Programs Directors) to encourage sufficient
trainees to choose a career in hematology. If funding for such a
career is an issue, and we believe that at present funding for training
in oncology is indeed better supported than that for hematology,
today’s leaders need to make concerted efforts to rectify the
imbalance. We suggest that current leaders have the obligation to
ensure that tomorrow’s children with hematological disorders will
be cared for as least as well as today’s children. That certainly
includes the availability of experts in that area and if that means that
today’s leaders need to lobby for better funding opportunities to
train pediatric hematologists, let’s get started. Perhaps ASPHO
should consider an impact analysis to document the number of
trainees pursuing careers in pediatric hematology compared to
oncology over the past 10 years.
We suggest that Pediatric Departments acknowledge and
publicly reward those who are successful in training pediatric
hematologists. Their achievement should be highlighted and cele-
brated at (inter)national meetings, to encourage ‘undifferentiated’
trainees to follow in their footsteps. Trainees in pediatric
hematology/oncology programs need to be informed of the ASH
Trainee Career Center web page. The web page contains a Grants
Clearinghouse which lists comprehensive research grants for
hematology trainees in various stages of training. The Grants
Clearinghouse (available to all ASH members as an Excel file)
provides grant opportunities available through ASH, NIH, other
federal agencies, as well as grants provided by selected patient
groups. We hope that by highlighting accomplishments and grant
opportunities in hematology that more individuals at the formative
point in their careers will pursue careers in pediatric hematology.
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